Three-weeks’ and weekly taxotere/cisplation treatment in non-small-cell lung cancer
- VernacularTitle:多西他赛联合顺铂三周方案与每周方案治疗非小细胞肺癌
- Author:
Yingbo CHEN
;
Jia CHEN
;
Lingxing CHEN
- Publication Type:Journal Article
- Keywords:
non-small-cell lung cancer;
taxotere;
cisplatin;
3-weeks’ treatment;
weekly treatment
- From:
China Oncology
2001;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose:To compare the response and toxic reaction of 3-weeks’ and weekly taxotere/cisplation treatment in non-small-cell lung cancer. Methods:Group A: Taxotere 75mg/m~2 IV d 1,cisplatin 25mg/m~2 d 1-3 q3-4w; Group B: Taxotere 60 mg IV d1, taxotere 40 mg IV d8,d15, cisplatin 25 mg/m~2 IV d 1,d 8,d 15 q3-4w. The clinical responses were assessed after two cycles. Toxicity was assessed every cycle. Results:There was no CR in the 71 cases . There were 14 PR, 13 SD in group A; there were 16 PR, 14 SD in group B. The overall response rates were 41.2% and 44.4% in group A and B. The rates of grade Ⅲ/Ⅳ neatropenia were 70.6% and 25% in group A and B. The major nonhematologic toxicity was weakness. The rates of weakness were 44.1% and 19.4% in group A and B. Conclusions:The response rates were similar between groups A and B. The occurrence of hematologic toxicity and weakness were lower in weekly treatment.
